Spero Therapeutics Q2 EPS $(0.23) Beats $(0.34) Estimate, Sales $2.72M Beat $1.07M Estimate
Portfolio Pulse from vinayak@benzinga.com
Spero Therapeutics reported Q2 earnings per share of $(0.23), beating the analyst consensus estimate of $(0.34) by 32.35%. The company also reported quarterly sales of $2.72 million, surpassing the analyst consensus estimate of $1.07 million by 153.83%. Both figures represent significant increases over the same period last year.
August 10, 2023 | 8:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Spero Therapeutics reported better than expected Q2 earnings and sales, which could positively impact the stock in the short term.
Spero Therapeutics reported Q2 earnings and sales that beat analyst estimates. This positive financial performance could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100